# Karuna Therapeutics, Inc., a Bristol trials: 23 (2026)

ClinicalTrials.gov lists 23 trials with Karuna Therapeutics, Inc., a Bristol Myers Squibb company as lead sponsor, 8 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Karuna Therapeutics, Inc., a Bristol Myers Squibb company: 23 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/karuna-therapeutics-inc-a-bristol-myers-squibb-company

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 8
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 7, 2026 | NCT07686263 | Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | Schizophrenia | 472 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686263) |
| July 2, 2026 | NCT07681076 | Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 4 | Recruiting | Healthy Volunteers | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681076) |
| February 20, 2026 | NCT07424404 | A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in... | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | Schizophrenia, Autism-Related Irritability | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424404) |
| December 2, 2025 | NCT07257120 | KarXT Concentrations in the Breast Milk and Plasma of Lactating Females | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 4 | Completed | Healthy Volunteers | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07257120) |
| October 2, 2025 | NCT07204418 | A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult... | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 1 | Recruiting | Healthy Volunteers | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07204418) |
| August 12, 2025 | NCT07118215 | A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 1 | Completed | Healthy Volunteers | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07118215) |
| December 12, 2024 | NCT06729970 | A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the... | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 1 | Completed | Healthy Volunteers | 133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06729970) |
| September 20, 2024 | NCT06605950 | A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and... | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 1 | Completed | Healthy Volunteers | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06605950) |
| September 19, 2024 | NCT06585787 | A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | Alzheimer Disease | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06585787) |
| August 27, 2024 | NCT06572449 | Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Completed | Schizophrenia | 173 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06572449) |
| November 13, 2023 | NCT06126224 | A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | Psychosis Associated With Alzheimer's Disease | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06126224) |
| August 8, 2023 | NCT05980949 | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's... | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | Psychosis Associated With Alzheimer's Disease | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05980949) |
| June 26, 2023 | NCT05919823 | A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Completed | Schizophrenia | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05919823) |
| December 8, 2022 | NCT05643170 | An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5... | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Terminated | Schizophrenia | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05643170) |
| August 23, 2022 | NCT05511363 | A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | Psychosis Associated With Alzheimer's Disease | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05511363) |
| March 31, 2022 | NCT05304767 | An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of... | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Completed | Schizophrenia | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05304767) |
| December 6, 2021 | NCT05145413 | A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Completed | Schizophrenia | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05145413) |
| March 29, 2021 | NCT04820309 | An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Completed | Schizophrenia | 566 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04820309) |
| February 4, 2021 | NCT04738123 | A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Completed | Schizophrenia, Schizophrenia; Psychosis | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04738123) |
| December 9, 2020 | NCT04659174 | An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Completed | Schizophrenia | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04659174) |
| December 9, 2020 | NCT04659161 | A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Completed | Schizophrenia, Schizophrenia; Psychosis | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04659161) |
| October 5, 2018 | NCT03697252 | A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 2 | Completed | Schizophrenia | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03697252) |
| July 13, 2016 | NCT02831231 | Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 1 | Completed | Schizophrenia | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02831231) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 15 |
| Phase 4 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 14 |
| Recruiting | 8 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 13 |
| Psychotic Disorders | 3 |
| Autistic Disorder | 1 |
| Nausea | 1 |
| Vomiting | 1 |
| Disease | 1 |
| Mental Disorders | 1 |
| Alzheimer Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Food and beverage exporters in the United States](https://specstream.ai/data/businesses/food-and-beverage-exporters/united-states)
- [Auto lenders in the United States](https://specstream.ai/data/businesses/auto-lenders/united-states)
- [Plastic and reconstructive surgery practices in the United States](https://specstream.ai/data/businesses/plastic-and-reconstructive-surgery-practices/united-states)
- [Filipino restaurants in the United States](https://specstream.ai/data/businesses/filipino-restaurants/united-states)
- [Appliance repair companies in the United States](https://specstream.ai/data/businesses/appliance-repair-companies/united-states)
- [Pediatric neurology practices in the United States](https://specstream.ai/data/businesses/pediatric-neurology-practices/united-states)
